In This Article:
LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.
The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2024 and decided that no dividend should be declared for the financial year 2024.
The AGM discharged the Board members and the Managing Director from liability and re-elected the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger. Leonard Kruimer was re-elected Chairman of the Board.
The AGM resolved that the Board's fee shall amount to SEK 899,875 to the Chairman of the Board, SEK 575,000 to a vice chairman of the Board and SEK 488,750 to each of the other Board members, who are not employed by the company. In addition hereto, the AGM resolved on fees for committee work of (i) SEK 80,500 to the Chairman of the Audit Committee and SEK 57,500 to other members of the Audit Committee, (ii) SEK 40,250 to the Chairman of the Remuneration Committee and SEK 28,750 to other members of the Remuneration Committee, and (iii) SEK 80,500 to the Chairman of the R&D Committee and SEK 57,500 to other members of the R&D Committee.
The AGM resolved to adopt the Board's report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.
Further, the AGM resolved to approve the Board's proposal regarding the implementation of a long-term incentive program in the form of an option program comprising all employees and other key persons in the company. The option program comprises a maximum of 980,000 stock options and the participants may be allotted options free of charge based on performance and continued employment. Each option entitles the holder to subscribe for one new share in BioInvent during the period from the day of release of the company's year-end report for the financial year 2027 up to and including February 28, 2029. The subscription price per share shall correspond to 125 per cent of the volume-weighted average price paid for the company's share on Nasdaq Stockholm during ten trading days as from and including April 29, 2025. To enable the company's delivery of shares pursuant to the option program and to secure costs connected therewith, primarily social security charges, the AGM resolved on a directed issue of a maximum of 1,136,800 warrants (corresponding to approximately 1.64 per cent of the total number of shares and votes in the company) and approval of transfer of warrants.